A reduction in LPL activity as part of breast cancer therapy combined with additional therapies to reduce hypertriglyceridemia, such as fenofibrate [49] and high‐dose omega‐3 fatty acids [50], may protect against the hypertriglyceridemia burden; however, this remains to be examined. This evidence concerns the gene LPL and breast carcinoma.